We’ve made it easier for you to access information and share content about biotechnology and prescription medicines. Click on or flip over any of the cards below to learn more about a topic. The information you discover can easily be shared on Twitter, Facebook and LinkedIn.
The Rare Pediatric Disease Priority Review Program (RPD PRV) was established to incentivize the development of therapies to treat rare pediatric diseases. The RPD PRV achieves this goal by granting a priority review voucher to a drug developer who develops and gains approval for a therapy that treats a rare pediatric disease.
There is a great wealth of American innovation that is trapped as a result of FDA’s approach to animal biotechnology, which treats biotech animals as containing “drugs.” A joint agreement between USDA and FDA that changes this approach will free innovation to the benefit of farmers, families, and the U.S. economy.
Innovations in animal biotechnology can improve human and animal health, make our farming and food systems more sustainable, and boost our bioeconomy. But these breakthroughs are dependent on a clear, timely, and science based regulatory approval process that provides a viable path to market.
Animal biotechnology has enormous potential to address several agricultural, environmental, humanitarian, and public health challenges. In order for these solutions to be realized, the U.S. must act now and develop a sensible, science-based regulatory approval process that provides these technologies with a viable path to market.
Gene Therapy. Immunotherapy. Precision Medicine. We’ve come too far to let government mandates, even harmless sounding ones, threaten progress in biomedical research.
The Power of Innovation in Addressing the Opioid Epidemic